Gastrointestinal (GI): NSAIDs that block COX-1 activity have correlations with GI complications due to inhibition with the synthesis of gastroprotective agents like PGE2 as well as other prostaglandins. This inhibition leads to reduced mucin manufacturing by gastric epithelial cells, fewer bicarbonate secretion, and fewer epithelial cell turnover, between other actions. https://jenningsm146svx2.theideasblog.com/profile